Flow chart showing screening of patients for Coartem® efficacy study, Metehara, Oct 2014-Jan 2015.

<p>Flow chart showing screening of patients for Coartem® efficacy study, Metehara, Oct 2014-Jan 2015.</p

The 28-day cure rate of Coartem®, Metehara, Ethiopia, Oct 2014 to Jan 2015.

<p>The 28-day cure rate of Coartem®, Metehara, Ethiopia, Oct 2014 to Jan 2015.</p

Survival analysis of 28-day cure rate of Coartem®, Metehara, Oct 2014-Jan 2015.

<p>Survival analysis of 28-day cure rate of Coartem®, Metehara, Oct 2014-Jan 2015.</p

Degree of parasitemia among study participants, Metehara, Oct 2014-Jan 2015.

<p>Degree of parasitemia among study participants, Metehara, Oct 2014-Jan 2015.</p

Mean difference in hemoglobin among participants, Metehara, Oct-Jan 2014/5.

<p>Mean difference in hemoglobin among participants, Metehara, Oct-Jan 2014/5.</p

Parasite and fever clearance in Coartem efficacy study, Metehara, Oct 2014-Jan 2015.

<p>Parasite and fever clearance in Coartem efficacy study, Metehara, Oct 2014-Jan 2015.</p

An association between parasitemia and fever, Metehara, Oct-Jan 2014/5.

<p>An association between parasitemia and fever, Metehara, Oct-Jan 2014/5.</p

Baseline characteristics of the study participants, Metehara, Oct 2014-Jan 2015.

<p>Baseline characteristics of the study participants, Metehara, Oct 2014-Jan 2015.</p

Temporal changes in the frequency of <i>Pfdhfr</i> and <i>Pfdhps</i> single nucleotide mutations between 2005 and 2007/08.

<p>The asterisk indicates the statistical significance of the difference according to Fisher’s exact test.</p

Change in the frequency of <i>Pfdhfr</i> and <i>Pfdhps</i> wild type alleles.

<p>The percentage frequency of wild type alleles in <i>Pfdhfr</i> single and triple (Ser-108/Asn-51/Cys-59), <i>Pfdhps</i> single and double (Ala-437/Lys-540) and quintuple wild types (Ser-108/Asn-51/Cys-59/Ala-437/Lys-540) were compared between 2005 and 2007/08. The asterisk indicates the statistical significance of the difference according to Fisher’s exact test.</p